JPWO2021087399A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021087399A5 JPWO2021087399A5 JP2022525291A JP2022525291A JPWO2021087399A5 JP WO2021087399 A5 JPWO2021087399 A5 JP WO2021087399A5 JP 2022525291 A JP2022525291 A JP 2022525291A JP 2022525291 A JP2022525291 A JP 2022525291A JP WO2021087399 A5 JPWO2021087399 A5 JP WO2021087399A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- reduction
- treatment
- determined
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 28
- 230000004410 intraocular pressure Effects 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 208000028389 Nerve injury Diseases 0.000 claims description 12
- 208000030533 eye disease Diseases 0.000 claims description 12
- 230000008764 nerve damage Effects 0.000 claims description 12
- 210000001328 optic nerve Anatomy 0.000 claims description 12
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 7
- 201000002761 non-arteritic anterior ischemic optic neuropathy Diseases 0.000 claims description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 239000004090 neuroprotective agent Substances 0.000 claims description 6
- 230000002207 retinal effect Effects 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 238000012377 drug delivery Methods 0.000 claims description 4
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 230000010412 perfusion Effects 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 2
- 229940122728 Caspase 2 inhibitor Drugs 0.000 claims description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims description 2
- -1 Verisome Substances 0.000 claims description 2
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 claims description 2
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims description 2
- 229960002610 apraclonidine Drugs 0.000 claims description 2
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims description 2
- 201000002763 arteritic anterior ischemic optic neuropathy Diseases 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 229960004324 betaxolol Drugs 0.000 claims description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 229960003679 brimonidine Drugs 0.000 claims description 2
- QZHBYNSSDLTCRG-WUUYCOTASA-N brimonidine tartrate Chemical compound [H+].[H+].[O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O.C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 QZHBYNSSDLTCRG-WUUYCOTASA-N 0.000 claims description 2
- 229960000722 brinzolamide Drugs 0.000 claims description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 2
- 229940127243 cholinergic drug Drugs 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229960003933 dorzolamide Drugs 0.000 claims description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- 229940029200 iluvien Drugs 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 230000003547 miosis Effects 0.000 claims description 2
- 239000003604 miotic agent Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 229950009210 netarsudil Drugs 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 229940083224 ozurdex Drugs 0.000 claims description 2
- 229960001416 pilocarpine Drugs 0.000 claims description 2
- 229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 125000003259 prostaglandin group Chemical group 0.000 claims description 2
- 229940061341 retisert Drugs 0.000 claims description 2
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 239000008181 tonicity modifier Substances 0.000 claims description 2
- 229960002368 travoprost Drugs 0.000 claims description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 2
- 230000004304 visual acuity Effects 0.000 claims description 2
- 229940053728 vitrasert Drugs 0.000 claims description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063020A JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928092P | 2019-10-30 | 2019-10-30 | |
| US62/928,092 | 2019-10-30 | ||
| US202063068215P | 2020-08-20 | 2020-08-20 | |
| US63/068,215 | 2020-08-20 | ||
| PCT/US2020/058411 WO2021087399A1 (en) | 2019-10-30 | 2020-10-30 | Treatment of ocular diseases using endothelin receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063020A Division JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022554277A JP2022554277A (ja) | 2022-12-28 |
| JP2022554277A5 JP2022554277A5 (https=) | 2023-11-07 |
| JPWO2021087399A5 true JPWO2021087399A5 (https=) | 2023-11-07 |
| JP7664239B2 JP7664239B2 (ja) | 2025-04-17 |
Family
ID=75715356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525291A Active JP7664239B2 (ja) | 2019-10-30 | 2020-10-30 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| JP2025063020A Pending JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063020A Pending JP2025106418A (ja) | 2019-10-30 | 2025-04-07 | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US11738007B2 (https=) |
| EP (2) | EP4050997A4 (https=) |
| JP (2) | JP7664239B2 (https=) |
| CN (2) | CN118203574A (https=) |
| AU (1) | AU2020373065A1 (https=) |
| CA (1) | CA3158767A1 (https=) |
| IL (1) | IL292350A (https=) |
| MX (1) | MX2022005063A (https=) |
| WO (1) | WO2021087399A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| WO2021087399A1 (en) | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| CN115103842A (zh) | 2020-02-06 | 2022-09-23 | 珀弗斯治疗股份有限公司 | 用于治疗眼部疾病的组合物 |
| CA3218251A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| AU2022264438A1 (en) * | 2021-04-30 | 2023-11-23 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| EP4346720A4 (en) | 2021-05-28 | 2025-01-01 | Sight Sciences, Inc. | INTRAOCULAR DEVICES, SYSTEMS AND METHODS |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993020784A1 (en) * | 1992-04-10 | 1993-10-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| JPH0959173A (ja) * | 1995-08-21 | 1997-03-04 | Santen Pharmaceut Co Ltd | 毛様体筋緊張緩和剤 |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2004525890A (ja) * | 2001-02-02 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤 |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| CA2759795C (en) | 2009-04-30 | 2016-11-29 | Midwestern University | Method and composition for treating diabetic ketoacidosis |
| WO2010144477A2 (en) | 2009-06-12 | 2010-12-16 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| EP2558103A4 (en) | 2010-04-12 | 2013-09-25 | R Tech Ueno Ltd | PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM |
| UA117274C2 (uk) * | 2013-12-19 | 2018-07-10 | Тасос Гєоргіу | Спосіб лікування, зменшення інтенсивності або профілактити захворювань, обумовлених ураженням зорового нерва |
| ES2584534B1 (es) * | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| KR20180021741A (ko) * | 2015-05-29 | 2018-03-05 | 에쥐 세라피틱스, 인코포레이티드 | 시각 손실을 감소시키기 위한 조성물 및 방법 |
| WO2017217967A1 (en) * | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| SG11201912267SA (en) * | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| EP3654941A1 (en) * | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| WO2021087399A1 (en) | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| CN115103842A (zh) * | 2020-02-06 | 2022-09-23 | 珀弗斯治疗股份有限公司 | 用于治疗眼部疾病的组合物 |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
-
2020
- 2020-10-30 WO PCT/US2020/058411 patent/WO2021087399A1/en not_active Ceased
- 2020-10-30 EP EP20881057.2A patent/EP4050997A4/en active Pending
- 2020-10-30 CN CN202410236817.2A patent/CN118203574A/zh active Pending
- 2020-10-30 IL IL292350A patent/IL292350A/en unknown
- 2020-10-30 EP EP22176530.8A patent/EP4094759A1/en active Pending
- 2020-10-30 MX MX2022005063A patent/MX2022005063A/es unknown
- 2020-10-30 AU AU2020373065A patent/AU2020373065A1/en active Pending
- 2020-10-30 CN CN202080076957.8A patent/CN114786480B/zh active Active
- 2020-10-30 CA CA3158767A patent/CA3158767A1/en active Pending
- 2020-10-30 JP JP2022525291A patent/JP7664239B2/ja active Active
-
2022
- 2022-04-29 US US17/733,216 patent/US11738007B2/en active Active
- 2022-04-29 US US17/733,210 patent/US20220257505A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/345,514 patent/US20240189288A1/en active Pending
-
2024
- 2024-12-10 US US18/976,033 patent/US20250099435A1/en active Pending
-
2025
- 2025-04-07 JP JP2025063020A patent/JP2025106418A/ja active Pending
- 2025-11-21 US US19/397,828 patent/US20260076948A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Casson | Medical therapy for glaucoma: A review | |
| Aihara et al. | Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study | |
| JP7670945B2 (ja) | 老眼、散瞳、および他の眼障害の治療のための方法および組成物 | |
| Soltau et al. | Changing paradigms in the medical treatment of glaucoma | |
| McLaren | Measurement of aqueous humor flow | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| CN114786480B (zh) | 使用内皮素受体拮抗剂治疗眼部疾病 | |
| CN113164451A (zh) | 治疗青光眼的方法和组合物及相关病症 | |
| CA3140889A1 (en) | Carbachol-brimonidine formulations to enhance anti-presbyopia effects | |
| Ha et al. | Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal‐tension glaucoma: the randomized phase II study | |
| JPWO2021087399A5 (https=) | ||
| KR100499903B1 (ko) | 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제 | |
| WO2023221852A1 (zh) | 一种用于治疗青光眼的复方药物组合物及其用途 | |
| Weinreb et al. | Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure | |
| WO2003004058A1 (fr) | Agents de protection du nerf optique contenant un bloqueur de recepteur $g(a)1 en tant qu'ingredient actif | |
| Miller-Ellis et al. | Then and Now: Medical Therapy for Glaucoma | |
| CN115998888A (zh) | 用于治疗青光眼或高眼压症的药物组合物及其用途 | |
| US11207341B2 (en) | TGF-beta oligonucleotide for use in treatment of ophthalmic diseases | |
| KR100938233B1 (ko) | 프로스타글란딘계 점안용 조성물과 그의 제조 방법 | |
| Kish | Old and new drug classes expanding to include glaucoma treatments | |
| Higginbotham | Will latanoprost be the'wonder'drug of the'90s for the treatment of glaucoma? | |
| US20260083712A1 (en) | Methods for treating patients with ocular comorbidities of an autoimmune disorder | |
| Abdolmejed et al. | Ocular complications of intravitreal avastin: a report from tobruk medi-cal center | |
| RENGARAJ VENKATESH | COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS |